Liver Function Abnormalities in Patients With Acute Heart Failure

Liver Function Abnormalities in Patients With Acute Heart Failure in Sohag University Hospitals

The aim of this study is to evaluate liver function test abnormalities and to identify associated cardiac and non cardiac factors mediating hepatic impairment in acute heart failure patients

Study Overview

• Status: Not yet recruiting
• Conditions: Acute Heart Failure
• Intervention / Treatment: Behavioral: Avoiding the risk factors

Detailed Description

Cardiac failure has a negative impact on the function of all parenchymatous organs, based both on the low organ perfusion in the left-sided failure and on the venous congestion in the right-sided failure.

The pathophysiology of acute heart failure (AHF) is complex and not fully understood. It has been hypothesized that an episode of acute decompensation affects not only the cardiovascular system itself, but may also deteriorate the function of other organs, c ausing serious clinical consequences. Liver involvement has been mostly described and investigated in patients with chronic HF.

Liver enzyme alterations are usually classified as relating predominantly to liver cell necrosis (signified by transaminase elevations) or predominantly to cholestasis (signified by elevated alkaline phosphatase (AP) level).

• Study Type: Observational
• Enrollment (Estimated): 100

Contacts and Locations

• Study Contact: Name: Sara Mohamed; Phone Number: +201117517685; Email: Sara_mohamed_post@med.Sohag.edu.eg
• Study Contact Backup: Name: Hassan Ahmed; Phone Number: +201003459741

Study Locations

• Egypt
  • Sohag, Egypt
    • Sohag University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: N/A

• Sampling Method: Probability Sample

Study Population

patients aged 18 yrs or older presenting with AHF

Description

Inclusion Criteria:

• patients aged 18 yrs or older presenting with AHF

Exclusion Criteria:

• Congenital heart disease
• acute and chronic liver diseases

Study Plan

How is the study designed?

Number of groups / cohorts

5

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Acute decompensated heart failure (de novo or as decompensation of chronic heart failure); This umbrella term includes patients presenting forthe first time with typical symptoms and signs of heart failure(de novo AHF) and also those with worsening of their pre-existing cardiomyopathy (acute decompensated heart failure).	Behavioral: Avoiding the risk factors; Exercise, Salt and lipid reduction in diet, smoking cessation
Pulmonary edema; It's the real clinical presentation of AHF, typically, signs and symptoms develope rapidly and patients demonstrate severe respiratory distress with tachypnea, orthopnea and pulmonary congestion	Behavioral: Avoiding the risk factors; Exercise, Salt and lipid reduction in diet, smoking cessation
Hypertensive acute heart failure; the condition is associated with elevated blood pressure with accompanying dyspnea. orthopnea and pulmonary congestion, often in patients with relatively preserved left ventricle ejection fraction	Behavioral: Avoiding the risk factors; Exercise, Salt and lipid reduction in diet, smoking cessation
cardiogenic shock; severe peripheral hypoperfusion wih subsequent end organs damage,typically it's associated with low blood pressure and low urine output	Behavioral: Avoiding the risk factors; Exercise, Salt and lipid reduction in diet, smoking cessation
Acute coronary syndrome complicated by heart failure; characterized by complex structural, hemodynamic and neurohormonal interaction need urgent referral for coronary intervention poor outcome	Behavioral: Avoiding the risk factors; Exercise, Salt and lipid reduction in diet, smoking cessation

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Liver function abnormalities in patients with acute heart failure in Sohag University Hospitals	assessment the LFTs abnormalities and factors mediating hepatic impairment in patients with AHF	baseline

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Liver function abnormalities in patients with acute heart failure in Sohag University Hospitals	assessment the LFTs abnormalities and factors mediating hepatic impairment in patients with AHF	1 year

Collaborators and Investigators

• Sponsor: Sohag University
• Investigators: Study Chair: Hamdy Saad, Sohag University; Study Chair: Haitham Mohammad, Sohag University

Study record dates

Study Major Dates

• Study Start (Estimated): July 1, 2024
• Primary Completion (Estimated): July 1, 2025
• Study Completion (Estimated): August 1, 2025

Study Registration Dates

• First Submitted: July 1, 2024
• First Submitted That Met QC Criteria: July 1, 2024
• First Posted (Actual): July 9, 2024

Study Record Updates

• Last Update Posted (Actual): July 10, 2024
• Last Update Submitted That Met QC Criteria: July 8, 2024
• Last Verified: July 1, 2024

More Information

Terms related to this study

• Keywords: LFTs, AHF
• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Heart Failure
• Other Study ID Numbers: LFTs abnormalities in AHF

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No